


## Johnson & johnson brings new lens for astigmatism patients in India

26 December 2022 | News

New TECNIS Synergy<sup>™</sup> Toric II OptiBlue® PC-IOL offers an opportunity to address both presbyopia and astigmatism at the time of cataract surgery



Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, has announced the availability of TECNIS Synergy™ Toric II OptiBlue® PC-IOL for patients with astigmatism in India.

TECNIS Synergy<sup>™</sup> Toric II IOL, is a continuous-range-of-vision lens engineered for rotational stability, which locks in visual performance and provides high-quality vision.

Cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes, with more than 90% of people developing cataracts by the age of 65. Most people will develop cataracts at some point in their life, and modern cataract surgery is a safe and effective treatment that has a success rate of nearly 98%.

In India, nearly 73% of adults 60 years and older have cataracts and if left untreated, cause vision to deteriorate over time. Astigmatism reduces distance and near visual acuity, vision quality, and depth perception. All cataracts will eventually need to be surgically removed and replaced with an artificial lens, called an IOL (Intraocular lens).

In India, TECNIS Synergy<sup>™</sup> Toric II OptiBlue<sup>®</sup> PC-IOL has been approved by the Central Drugs Standard Control Organisation (CDSCO).

Burzin Shahana, Country Manager at Johnson & Johnson Vision, Surgical Vision India, said, "TECNIS Synergy<sup>™</sup> Toric II OptiBlue® PC-IOL is an advanced IOL solution for cataract patients with astigmatism and gives patients the visual clarity and increased spectacle independence to improve their current lifestyles." He also added, "The launch will also expand available options physicians have to provide value to their patients with astigmatism."